Fig. 1A DNA and Amino Acid Sequence of Variable Region of FR1-H7 Heavy Chain

Heavy chain variable region sequence (cDNA)

Heavy chain variable region sequence (amino acid)

 $\label{eq:maevqlvqsgaevkkpgasvkvsckvsgytftdyymhwvqqapgkglewmg LVDPEDGETIYAEKFQGRVTITADTSTDTAYMELSSLRSEDTAVYYCARDDYMD VWGKGTLVTVSSASTKGP$ 

Fig. 1B DNA and Amino Acid Sequence of Variable Region of FR1-H7 light Chain

Light chain variable region sequence (cDNA)

CTTGAAACGACACTCACGCAGTCTCCAGACACCCTGTCTTTGTCTCCAGGAGA
AGGAGCCACCCTCTCCTGTAGGGCCAGTCAGAGTGTTAGCGGCAGTGCGTTG
GCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGACTCCTCATCTATGATG
CATCCAGTAGGGCCACTGGCGTCCCAGACAGGTTCAGTGGCAGTGGGTCTGG
GGCAGACTTCAGTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTG
TATTCCTGTCAGCAATATGGTAGCTCACCTCTCACTTTCGGCCCTGGGACCAA
AGTGGATGTCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCAT
CTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAAC
TTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATT

Light chain variable region sequence (amino acid)

LETTLTQSPDTLSLSPGEGATLSCRASQSVSGSALAWYQQKPGQAPRLLIYDASS RATGVPDRFSGSGSGADFSLTISRLEPEDFAVYSCQQYGSSPLTFGPGTKVDVKR TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVD

# Fig. 1C CDRs For FR1-H7 Nucleic Acid Sequences

#### VH (human heavy chain subclass I)

CDR1 GACTACTACATGCAC

CDR2 CTTGTTGATCCTGAAGATGGTGAAACAATCTACGCAGAGAAGTTCCAGGGC

CDR3 GATGACTACATGGACGTC

## VL (human kappa light chain subgroup III)

CDR1	AGGGCCAGTCAGAGTGTTAGCGGCAGTGCGTTGGCC
0000	

CDR2 GATGCATCCAGTAGGGCCACT

CDR3 CAGCAATATGGTAGCTCACCT

#### Fig. 1D CDRs For FR1-H7 Amino Acid Sequences

## VH (human heavy chain subclass I)

CDR1

DYYMH

CDR2

LVDPEDGETIYAEKFQG

CDR3

DDYMDV

#### VL (human kappa light chain subgroup III)

CDR1

RASQSVSGSALA

CDR2

DASSRAT

CDR3

QQYGSSPLT

Fig. 2A DNA and Amino Acid Sequence of Variable Region of FR1-A1 Heavy Chain

Heavy chain variable region sequence (cDNA)

Heavy chain variable region sequence (amino acid)

 $\label{eq:maqvqlvqsgaevkkpgssvkvsckasgqtftgyymhwvrqapgqglewmg RIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGGDLGG MDVWGQG$ 

Fig. 2B DNA and Amino Acid Sequence of Variable Region of FR1-A light Chain

Light chain variable region sequence (cDNA)

CTTGAAATTGTGCTGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGA GCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCGGCATAGTAATGGA TACAACTATTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCT GATCTATTTGGCTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCA GTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGA TGTTGGGGTTTATTACTGCATGCAAGCTCTACAAATTCCTCCGACTTTCGGCC CTGGGACCAAAGTGGATATCAAACGAACTGTGGCTGCA

Light chain variable region sequence (amino acid)

LEIVLTQSPLSLPVTPGEPASISCRSSQSLRHSNGYNYLDWYLQKPGQSPQLLIYL ASNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQIPPTFGPGTKVD IKRTVAA

#### Fig. 2C CDRs For FR1-A1 Nucleic Acid Sequences

#### VH (human heavy chain subclass I)

CDR1 GGCTACTATATGCAC

CDR2 AGGATCATCCCTATCCTTGGTATAGCAAACTACGCACAGAAGTTCCAGGGC

CDR3 GGAGGAGATCTGGGCGGTATGGACGTC

#### VL (human kappa light chain subgroup II)

 ${\bf CDR1} \quad {\bf AGGTCTAGTCAGAGCCTCCGGCATAGTAATGGATACAACTATTTGGAT}$ 

CDR2 TTGGCTTCTAATCGGGCCTCC

CDR3 ATGCAAGCTCTACAAATTCCTCCGACT

## Fig. 2D CDRs For FR1-A1 Amino Acid Sequences

## VH (human heavy chain subclass I)

CDR1

GYYMH

CDR2

RIIPILGIANYAQKFQG

CDR3

GGDLGGMDV

## VL (human kappa light chain subgroup II)

CDR1

RSSQSLRHSNGYNYLD

CDR2

LASNRAS

CDR3

MQALQIPPT

Fig. 3




Fig. 4A




Fig. 4B




Fig. 5A




Fig. 5B




Fig. 6

FGF-2			20	
(ng/ml)	-	20	20	-
FR1-H7		••		
(μg/ml)	-	30	-	30

Molecular weight marker




Fig. 7




Fig. 8A




Fig. 8B





Fig. 9



<sup>\*13</sup> gram mouse euthanized

Fig. 10




Fig. 11




Fig. 12A




Fig. 12B




Fig. 13




Fig. 14




Fig. 15A




Fig. 15B




Fig. 15C




Fig. 15D




Fig. 16




Fig. 17




Fig. 18




Fig. 19




Fig. 20




Fig. 21




Fig. 22

FGF-2 (ng/ml) FR1-A1 - 10 10 - (μg/ml)

Fig. 23




Fig. 24




Fig .25




Fig. 26A




Fig. 26B




Fig 26C




Fig. 26D




Fig. 26E




Fig. 27A





Fig. 27B






Fig. 27C





Fig. 27D



 ${\tt FGGGTKLTVLG}$ 

100

111

Fig. 28A. FR1-4H antibody variable sequences

# Heavy chain variable region sequence (cDNA) (gamma heavy chain)

(gamma heavy chain)	
CAGGTGCAGCTGGTGAGTTTGGCCCAGGACTGGTGAAGCCTTCGGAGAC CCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGTAGTTACTACT GGAGCTGGATCCGGCAGCCCCCAGGGAAGGGA	50 100 150 200 250 300 350
GACCACGGTCACCGTCTCAAGC	372
Heavy chain variable region sequence (amino acid)	
QVQLVEFGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGY IYYSGSTNYNPSLKSRVAISVDTSKNQFSLKLSSVTAADTAVYYCAREYY YDSSGYYFYAFDIWGQGTTVTVSS	50 100 124
Light chain variable region sequence (cDNA)	
CTGCCTGTGCTGACTCAGCCCCCTCAGCGTCTGGGACCCCCGGGCAGAG GGTCTCCATCTTGTTCTGGAAGCAGCTCCAACATCGGAAGTAATTATG TATACTGGTACCAGCAGCTCCCAGGAACGGCCCCCAAACTCCTCATCTTT AGGAATAATCAGCGGCCCTCAGGGGTCCCTGACCGATTCTCTGGCTCCAA GTCTGGCACTTCAGCCTCCCTGGCCATCAGTGGGCTCCGAGGATG AGGCTGATTATTACTGTGCAGCATGGGATGACAGCCTGAGTGGTTGGGTG TTCGGCGGAGGGACCAAGCTGACCGTCCTAGGT	50 100 150 200 250 300 333
Light chain variable region sequence (amino acid). (Lambda light chain)	
LPVLTQPPSASGTPGQRVSISCSGSSSNIGSNYVYWYQQLPGTAPKLLIF	50

 ${\tt RNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGWV}$ 

# Fig. 28B. FR1-4H antibody variable sequence CDRs

#### CDR amino acid sequences

#### V<sub>H</sub>:

CDR1

SYYWS

CDR2 CDR3 YIYYSGSTNYNPSLKS

EYYYDSSGYYFYAFDI

 $V_L$ :

CDR1

SGSSSNIGSNYVY

CDR2

RNNQRPS

CDR3

AAWDDSLSGWV

#### CDR nucleic acid sequences

#### $V_H$ :

CDR1

AGTTACTACTGGAGC

ČDR2 CDR3 GAGTATTACTATGATAGTAGTGGTTATTACTTTTATGCTTTTTGATATC

 $V_L$ :

CDR1

TCTGGAAGCAGCTCCAACATCGGAAGTAATTATGTATAC

CDR2

AGGAATAATCAGCGGCCCTCA

CDR3

GCAGCATGGGATGACAGCCTGAGTGGTTGGGTG

Fig. 29




Fig. 30. Examples of FGFR small molecule inhibitors.

#### Indolinone derivatives:

#### Quinolinone derivatives:

### Pyrimido-pyridine derivatives:

Fig. 31.

FGF		5 ng	5 ng	5 ng	5 ng	5 ng	5 ng
Pryimido-pyridines derivative A	-	-	0.5 μΜ	0.2 μΜ	0.1 μΜ	0.05 µM	0.02 μΜ

|--|

FGF		100 ng	100 ng	100 ng	100 ng
Pryimido-pyridines	-	-	0.1	0.03	0.01
derivative B			μM	μΜ	μМ



# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

#### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

<b>C</b>
☐ BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
LINES OR MARKS ON ORIGINAL DOCUMENT
REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

## IMAGES ARE BEST AVAILABLE COPY.

☐ OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.